Vanda Pharmaceuticals
Clinical trials sponsored by Vanda Pharmaceuticals, explained in plain language.
-
Psoriasis drug trial halted midway: what happened?
Disease control TerminatedThis study tested the long-term safety and effectiveness of imsidolimab, an experimental drug, in adults with generalized pustular psoriasis (GPP), a severe skin condition causing painful pustules. Participants had already completed an earlier phase of the study. The trial was te…
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 05:28 UTC
-
Promising ichthyosis drug trial halted early
Symptom relief TerminatedThis study tested a drug called imsidolimab (ANB019) for people with ichthyosis, a condition causing dry, scaly skin. The trial planned to enroll about 5 adults with moderate to severe symptoms and measure changes in skin severity over 16 weeks. However, the study was terminated …
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Symptom relief
Last updated May 15, 2026 11:56 UTC
-
Cancer rash study halted early: only 4 patients enrolled
Symptom relief TerminatedThis study tested a drug called ANB019 to treat acne-like rashes that can appear as a side effect of certain cancer medications (EGFR or MEK inhibitors). The goal was to see if the drug could reduce the number of pimples and bumps on the face. The study was stopped early and only…
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Symptom relief
Last updated May 11, 2026 20:53 UTC